List of Excipients in Branded Drug NEO-POLY-DEX

Generic Drugs Containing NEO-POLY-DEX

Company	Ingredient	NDC	Excipient
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	BENZALKONIUM CHLORIDE
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	HYDROCHLORIC ACID
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	HYPROMELLOSES
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	POLYSORBATE 20
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	SODIUM CHLORIDE
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	SODIUM HYDROXIDE
Butler Animal Health Supply	neomycin sulfate, polymyxin b sulfate and dexamethasone	11695-1403	WATER

What are the Most Frequently-Used Excipients in NEO-POLY-DEX?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	HYDROCHLORIC ACID
1	HYPROMELLOSES
1	LANOLIN
1	METHYLPARABEN
1	MINERAL OIL
1	PETROLATUM

NEO-POLY-DEX Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

NEO-POLY-DEX is an ophthalmic combination of neomycin sulfate, polymyxin B sulfate, and dexamethasone. Its commercial value is concentrated in formulation execution rather than active-ingredient exclusivity. The strongest opportunities are preservative-free delivery, improved suspension performance, lower-irritation excipients, unit-dose packaging, and differentiated ointment or gel formats.

The product is commercially exposed to generic competition because the active ingredients are established, the therapeutic combination is old, and meaningful patent protection is unlikely to block abbreviated new drug applications. Excipient innovation can still create regulatory and commercial differentiation, but it will not generally prevent substitution unless the product obtains a distinct formulation or delivery profile supported by clinical or bioequivalence data.

What is NEO-POLY-DEX and which dosage forms are marketed?

NEO-POLY-DEX is used for steroid-responsive inflammatory ocular conditions when bacterial infection or a risk of bacterial infection exists. The product combines:

Active ingredient	Function
Neomycin sulfate	Aminoglycoside antibacterial
Polymyxin B sulfate	Polypeptide antibacterial
Dexamethasone	Corticosteroid anti-inflammatory

The brand has historically been marketed in ophthalmic suspension and ophthalmic ointment formats. The formulations are not interchangeable from an excipient or development perspective.

NEO-POLY-DEX ophthalmic suspension

The suspension requires excipients that control:

• Sterile dispersion of the active ingredients
• Sedimentation and redispersibility
• Ocular residence time
• pH and tonicity
• Chemical stability
• Microbial control after opening
• Drop-size consistency

Published product labeling identifies excipient classes including suspending or viscosity agents, buffers, tonicity adjusters, chelating agents, pH adjusters, and purified water. Exact inactive ingredients can vary by dosage form, manufacturer, and approved product version. FDA labeling should control any regulatory or competitive assessment. (U.S. Food and Drug Administration, n.d.-a)

NEO-POLY-DEX ophthalmic ointment

The ointment uses a hydrophobic base, typically involving mineral oil and petrolatum-type materials. Its commercial attributes include longer ocular contact time, reduced dosing frequency in some use cases, and suitability for nighttime administration.

The tradeoff is reduced visual acuity immediately after application, greater patient perception of greasiness, and more difficult dose handling. Ointment excipient selection also affects drug release, microbial control, rheology, and tube compatibility.

What excipient strategy best supports NEO-POLY-DEX differentiation?

The highest-value strategy is to treat the excipient system as a delivery platform rather than as a low-cost formulation component.

1. Develop a preservative-free suspension

A preservative-free version would target patients with:

• Chronic or repeated ophthalmic treatment
• Ocular-surface disease
• Contact-lens-associated sensitivity
• Prior intolerance to benzalkonium chloride
• Postoperative or inflammatory conditions requiring repeated dosing

Multidose preservative-free packaging is technically more difficult than conventional multidose packaging. The system must control microbial ingress without relying on a conventional preservative. Options include:

• One-way valves
• Airless multidose containers
• Sterile unit-dose ampoules
• Blow-fill-seal packaging
• Low-dead-volume droppers

A preservative-free product could command a price premium, but the premium must offset higher container, filling, sterility-assurance, and stability costs.

2. Replace or minimize ocular-surface-irritating preservatives

Benzalkonium chloride is widely used in ophthalmic products but has recognized ocular-surface tolerability concerns, particularly with repeated exposure. A reformulation could evaluate:

• Polyquaternium-based preservation
• Oxidative preservative systems
• SofZia-type ionic systems
• Chlorobutanol or phenylmercuric alternatives where legally and commercially appropriate
• Preservative-free packaging

The development objective should not be simple preservative substitution. The sponsor would need to demonstrate comparable antimicrobial effectiveness, active stability, container compatibility, and clinical tolerability under the applicable FDA ophthalmic requirements. (U.S. Food and Drug Administration, 2019)

3. Improve suspension redispersibility

A poorly redispersing suspension creates dose variability and patient-use risk. A differentiated NEO-POLY-DEX suspension should optimize:

• Particle-size distribution
• Crystal morphology
• Sedimentation rate
• Resuspendability after storage
• Dose uniformity during the container-use period
• Drop size across bottle orientation and fill volume

Hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers, povidone, and related rheology modifiers can improve residence time and suspendability. Each excipient changes viscosity, drop formation, comfort, and filtration or sterilization feasibility.

A practical target is a suspension that redisperses with minimal shaking while maintaining a low-viscosity drop suitable for routine use. Excess viscosity can improve retention but can also increase blur, stringing, and dosing variability.

4. Use mucoadhesive excipients to extend residence time

A gel-forming or lightly mucoadhesive formulation could reduce washout through blinking and lacrimation. Potential excipient families include:

• Carbomers
• Sodium hyaluronate
• Cellulose derivatives
• Poloxamers
• Gellan gum
• Thiolated polymers

The commercial opportunity is strongest if the formulation reduces dosing frequency without materially impairing vision. The development program would need to establish ocular comfort, preservative compatibility, active release, and comparable therapeutic exposure.

5. Optimize pH and osmolality for tolerability

The product contains two antibiotics and a corticosteroid with different chemical and physical stability profiles. Excipient selection must balance:

• Dexamethasone stability
• Sulfate salt solubility
• Suspension stability
• Ocular comfort
• Container compatibility
• Microbial-control performance

A near-physiologic osmolality and tolerable pH can improve adherence, but the optimal range must be established through formulation and clinical testing rather than inferred from the individual active ingredients.

What formulations are protected by NEO-POLY-DEX-related intellectual property?

The original combination is unlikely to provide a commercially durable patent barrier by itself. The relevant protectable subject matter is more likely to involve a later formulation or delivery system.

Potential patentable features

Formulation feature	Potential claim focus	Commercial value
Preservative-free multidose bottle	Container, valve, dosing system, formulation	High
Improved suspension	Particle size, viscosity, redispersibility	Moderate to high
Mucoadhesive gel	Polymer system and release profile	Moderate
Low-irritation preservative system	Preservative combination and concentration	Moderate
Unit-dose suspension	Sterile fill, stability, container closure	Moderate
Ointment or gel hybrid	Base composition and drug release	Moderate
Manufacturing process	Sterilization, aseptic processing, particle control	Moderate
Reduced dosing frequency	Formulation plus method-of-use claims	High if clinically supported

Patent claims covering only routine excipient substitution are vulnerable to obviousness challenges. Stronger protection would combine a defined excipient system with measurable performance, such as improved redispersibility, reduced preservative exposure, extended residence time, or improved tolerability.

A formulation patent should avoid claims that depend solely on broad excipient categories. Claims are more defensible when they specify concentration ranges, viscosity windows, particle-size limits, preservative levels, container characteristics, and comparative performance.

When does NEO-POLY-DEX lose exclusivity?

NEO-POLY-DEX appears to be a mature ophthalmic combination rather than a product approaching first generic entry. The principal exclusivity risk is therefore ongoing generic substitution, not a near-term patent cliff.

Exclusivity profile

Exclusivity type	Assessment
Active-ingredient exclusivity	Expired or commercially irrelevant for the mature combination
Original formulation patents	Likely expired or limited in practical scope
New chemical entity exclusivity	Not applicable to the mature combination
Orphan exclusivity	Not applicable
Pediatric exclusivity	No meaningful current barrier identified
Formulation patents	Potentially relevant only to later differentiated products
Regulatory exclusivity	Dependent on any later reformulation or new clinical program

FDA-approved ophthalmic generics can compete through ANDA pathways when they demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements. Generic versions may differ in inactive ingredients unless the differences create safety or efficacy concerns. (U.S. Food and Drug Administration, n.d.-b)

What is the Orange Book status of NEO-POLY-DEX?

The Orange Book assessment must be made at the specific product and NDA level. NEO-POLY-DEX may not have the same listing profile across its suspension and ointment presentations, and an individual listed product may have no unexpired patents.

For commercial due diligence, the relevant review should cover:

1. The current reference-listed drug.
2. NDA identification.
3. Dosage form and strength.
4. Listed patents and expiration dates.
5. Any pediatric-exclusivity notation.
6. Approved generic products.
7. Therapeutic-equivalence codes.
8. Drug shortages or discontinuation status.

An absence of unexpired Orange Book patents does not eliminate all IP risk. A competitor could assert formulation, container, manufacturing, trade-secret, trademark, or non-Orange-Book patents. Orange Book-listed patents remain the clearest indicator of Paragraph IV exposure for an ANDA applicant. (U.S. Food and Drug Administration, n.d.-c)

Which companies are challenging NEO-POLY-DEX?

The mature ophthalmic antibiotic-steroid market is generally contested by generic manufacturers rather than by biosimilar developers. Likely competitive categories include:

• Large generic manufacturers
• Ophthalmology-focused specialty companies
• Contract manufacturers with sterile ophthalmic capacity
• Regional pharmaceutical companies
• Private-label distributors

A precise company-by-company challenge list requires current FDA approval records and litigation-docket review. The commercial fact pattern is clear: the primary threat comes from ANDA substitution and price competition, not biosimilar entry.

Are biosimilars relevant to NEO-POLY-DEX?

No. NEO-POLY-DEX contains small-molecule and peptide-like active ingredients in a conventional ophthalmic product. It is not a biologic and does not qualify for the biosimilar pathway under the Public Health Service Act.

The relevant competitive pathways are:

• ANDA approval for generic equivalents
• 505(b)(2) applications for materially differentiated formulations
• New drug applications for products with new clinical or delivery claims
• State-level pharmacy substitution based on therapeutic-equivalence status

A preservative-free, extended-residence, or novel-container version could be developed as a 505(b)(2) product if it relies partly on the reference product while introducing formulation or delivery changes. The regulatory burden would increase if the sponsor seeks new clinical claims or materially different dosing.

What generic entry risks exist for NEO-POLY-DEX?

Generic entry risk is high for conventional suspension and ointment products. The main commercial risks are:

Price erosion

Generic ophthalmic products can rapidly reduce reimbursement and wholesale pricing, particularly where several manufacturers have therapeutic-equivalence ratings. Brand retention depends on formulary position, prescriber preference, supply reliability, and patient familiarity.

Substitution

If a generic receives an FDA therapeutic-equivalence rating, pharmacies may substitute it under applicable state law unless the prescription or payer rules prevent substitution.

Supply disruption

Sterile ophthalmic manufacturing has higher operational complexity than many oral solid-dose products. Recalls, fill-finish failures, container defects, and manufacturing interruptions can create temporary supply opportunities for an alternative supplier.

Label similarity

A generic product with the same active ingredients, strength, dosage form, and route can compete without reproducing every brand excipient. This limits the defensive value of conventional excipient differences.

How strong is the patent estate for NEO-POLY-DEX?

The legacy patent estate is likely weak as a barrier to generic competition. The stronger opportunity is a new patent family directed to a specific differentiated product.

Patent-strength assessment

Patent subject	Likely strength
Neomycin-polymyxin B-dexamethasone combination	Low due to age and prior art
Conventional aqueous suspension	Low to moderate
Conventional petrolatum ointment	Low
Specific preservative-free container	Moderate to high
Defined particle-size and rheology profile	Moderate
Mucoadhesive extended-residence formulation	Moderate
Manufacturing process with validated performance	Moderate
New clinical use	Dependent on novelty and written description
Broad excipient substitution	Low

The most defensible portfolio would use layered claims:

• Composition claims
• Container-closure claims
• Manufacturing claims
• Method-of-use claims
• Dependent claims covering concentration and performance ranges

The sponsor should also protect formulation know-how through trade secrets, particularly sterilization conditions, homogenization parameters, particle-size control, suspension aging protocols, and filling-process settings.

What commercial opportunities exist beyond the legacy brand?

Preservative-free premium product

This is the most direct opportunity. A preservative-free product could target ophthalmologists, postoperative care providers, and patients with ocular-surface sensitivity.

Unit-dose product

Unit-dose packaging reduces preservative exposure and may improve portability. The disadvantages are higher packaging costs, more waste, and potentially lower patient convenience for extended treatment.

Gel suspension

A gel suspension could increase ocular residence time and support reduced dosing frequency. The principal risks are temporary visual blur and more difficult drop formation.

Nighttime ointment

An ointment remains useful where prolonged contact is more important than daytime visual clarity. A less greasy ointment or ointment-gel hybrid could compete on comfort and patient acceptance.

Hospital and ambulatory-surgery supply

Reliable sterile supply can create value even without strong patent protection. Hospitals and surgery centers may prioritize supply continuity, standardized packaging, and procurement economics.

International licensing

Potential licensing partners include:

• Sterile ophthalmic manufacturers
• Regional pharmaceutical companies
• Specialty ophthalmology distributors
• Companies with preservative-free packaging platforms
• Firms with established 505(b)(2) development capabilities

The strongest licensing asset would be a validated formulation with stability data, container compatibility, and an efficient regulatory pathway. A generic active-ingredient combination without formulation differentiation would have limited licensing leverage.

How does NEO-POLY-DEX compare with competing ophthalmic antibiotic-steroid products?

Product category	NEO-POLY-DEX position	Differentiation opportunity
Neomycin-polymyxin B-dexamethasone suspension	Established combination	Preservative-free delivery and improved redispersibility
Neomycin-polymyxin B-dexamethasone ointment	Longer residence time	Reduced greasiness and improved dosing
Tobramycin-dexamethasone	Strong physician familiarity	Tolerability, cost, and supply reliability
Ciprofloxacin-dexamethasone	Fluoroquinolone-based option	Stewardship positioning and narrower antibacterial profile
Gatifloxacin or moxifloxacin steroid combinations	Broad antibacterial positioning	Price and formulation simplicity
Steroid-only products	No antibacterial component	Infection-risk coverage where clinically appropriate

The product should not be positioned solely on the presence of three active ingredients. That composition is easy to copy. Differentiation should focus on patient experience, preservative burden, dosing convenience, sterility assurance, and supply performance.

What litigation and Paragraph IV issues affect NEO-POLY-DEX?

For a mature product, Paragraph IV litigation is most likely to arise only if an unexpired patent covers a later formulation, container, or method of use. A conventional generic applicant would typically evaluate:

• Orange Book patent listings
• Patent-term expiration
• Certificate of correction or pediatric extension
• Paragraph IV certification requirements
• Prior ANDA approvals
• Therapeutic-equivalence status
• Product-specific labeling differences

A Paragraph IV notice can trigger litigation and a 30-month stay under applicable conditions, but that mechanism is relevant only where a listed patent exists and the ANDA applicant certifies invalidity, unenforceability, or noninfringement. (U.S. Food and Drug Administration, n.d.-c)

Settlement agreements should be reviewed for:

• Authorized-generic rights
• Launch dates
• Supply arrangements
• Patent-license scope
• Acceleration clauses
• Product-specific restrictions
• FTC reporting obligations

No settlement should be assumed to protect the legacy product without a current docket and agreement review.

What manufacturing and IP barriers matter most?

The principal barrier is sterile ophthalmic manufacturing, not active-ingredient synthesis. Key manufacturing controls include:

• Aseptic processing or validated terminal sterilization where feasible
• Sterile filtration for compatible components
• Particle-size control
• Uniform suspension filling
• Container-closure integrity
• Extractables and leachables testing
• Preservative-effectiveness testing
• In-use stability
• Drop-size consistency
• Microbial limits and sterility testing

The most valuable manufacturing IP may remain confidential rather than patented. A competitor can often design around a formulation patent but may struggle to reproduce robust process capability without development data.

Key Takeaways

• NEO-POLY-DEX is a mature ophthalmic antibiotic-steroid combination with high generic-substitution exposure.
• Legacy active-ingredient and conventional formulation patents are unlikely to provide a durable commercial barrier.
• The strongest excipient opportunity is a preservative-free multidose or unit-dose system.
• Suspension redispersibility, particle-size control, ocular comfort, and extended residence time are practical differentiation targets.
• A differentiated product may support a 505(b)(2) strategy, depending on formulation changes and proposed claims.
• Biosimilar competition is irrelevant; ANDA and 505(b)(2) competition are the relevant pathways.
• Orange Book and Paragraph IV risk must be assessed at the specific NDA, dosage-form, and patent-listing level.
• Sterile manufacturing capability, supply reliability, and container technology may create greater commercial value than a conventional excipient patent.
• Licensing interest is likely to center on validated preservative-free delivery, not the legacy combination alone.

FAQs

Can a preservative-free NEO-POLY-DEX product obtain market exclusivity?

A preservative-free product may obtain patent protection or regulatory exclusivity if it contains a novel, nonobvious formulation or delivery system. Preservative removal alone is unlikely to create strong exclusivity without a technically defined and commercially meaningful improvement.

Is a NEO-POLY-DEX gel likely to require new clinical trials?

The requirement depends on the formulation change, dosing regimen, proposed labeling, and FDA determination. A 505(b)(2) application may rely partly on existing safety and efficacy information, but comparative studies and additional clinical evidence may be required for materially different exposure or dosing claims.

Which excipient creates the best commercial differentiation?

The container-excipient combination is likely to have the highest value. A preservative-free multidose package paired with a stable, easily redispersed suspension can address both ocular-surface tolerability and dosing consistency.

Can an ophthalmic ointment extend NEO-POLY-DEX patent life?

A new ointment composition could support separate patent claims if it has a novel base, release profile, stability advantage, or tolerability benefit. It would not automatically extend exclusivity for the legacy product.

Is NEO-POLY-DEX suitable for an authorized-generic strategy?

Yes. An authorized generic could compete on price and supply while preserving a branded or differentiated product for preservative-free, unit-dose, or specialty-channel use. The strategy is most attractive where the sponsor controls reliable sterile manufacturing and has channel-specific pricing discipline.

References

1. U.S. Food and Drug Administration. (n.d.-a). NEO-POLY-DEX ophthalmic suspension and ointment labeling. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2019). Guidance for industry: Ophthalmic drug products for topical delivery. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. U.S. Food and Drug Administration. (n.d.-d). Sterile drug products produced by aseptic processing: Current good manufacturing practice. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice